Naratriptan (GR-85548A)通过激活5-HT1B/1D受体,发挥收缩颅动脉及抑制三叉神经介导的炎症双重作用,是一种用于急性偏头痛研究的口服有效制剂。
|
英文别名 (English Synonym) |
Naratriptan |
|
中文名称 (Chinese Name) |
盐酸那拉曲坦；盐酸纳拉曲坦 |
|
靶点 (Target) |
5-HT Receptor |
|
通路 (Pathway) |
Neuroscience |
|
CAS号 (CAS NO.) |
143388-64-1 |
|
分子式 (Formula) |
C17H26ClN3O2S |
|
分子量 (Molecular Weight) |
371.93 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Connor HE, Feniuk W, Beattie DT, North PC, Oxford AW, Saynor DA, Humphrey PP. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia. 1997 May,17(3):145-52. doi: 10.1046/j.1468-2982.1997.1703145.x. PMID: 9170336.[2]Hoskin KL, Lambert GA, Donaldson C, Zagami AS. The 5-hydroxytryptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res. 2004 Feb 13,998(1):91-9. doi: 10.1016/j.brainres.2003.11.018. PMID: 14725972.
